Claudia Angela Maria Fulgenzi

Also affiliated with Imperial College London

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis”.

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

The Lancet Oncology(2024)10.1016/s1470-2045(24)00457-1

N/A

1.7DataRank · unranked

70 citations

Bernardo Stefanini, Julia Blanter, Benjamin Adegbite, Fionnuala Crowley, Vincent Yip +18 more

Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.06.001

N/A

0DataRank · unranked

28 citations

Rafee Talukder, Genevieve Ihsiu Lin, Leonidas Nikolaos Diamantopoulos, Scott J. Dawsey, Shilpa Gupta +47 more

Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.08.006

N/A

0DataRank · unranked

9 citations

Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas Nikolaos Diamantopoulos, Scott J. Dawsey, Shilpa Gupta +49 more

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

European Journal of Cancer(2022)10.1016/j.ejca.2022.08.024

N/A

0DataRank · unranked

112 citations

Jaekyung Cheon, Antonio D’Alessio, Naoshi Nishida, Celina Ang, Thomas U. Marron +32 more

Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab

JHEP Reports(2024)10.1016/j.jhepr.2024.101295

N/A

0DataRank · unranked

9 citations

Philipp Mildenberger, Jennifer Gile, Fabian Jost‐Brinkmann, Bernhard Scheiner, Catherine Leyh +54 more

Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study

JHEP Reports(2025)10.1016/j.jhepr.2025.101685

N/A

0DataRank · unranked

2 citations

Tiziana Pressiani, Naoshi Nishida, Shadi Chamseddine, Ashwini Arvind, Michael Li +36 more

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study

Hepatology Communications(2023)10.1097/hc9.0000000000000302

N/A

0DataRank · unranked

11 citations

Bernhard Scheiner, Antonio D ́Alessio, Claudia Angela Maria Fulgenzi, Martin Schönlein, Lorenz Kocheise +31 more